Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/11/21 16:32:13」(JST)

wiki en

Etofibrate is a fibrate. It is a combination of clofibrate and niacin, linked together by an ester bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to controlled-release formulations.^[1]

References[edit]

^ Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA (2001). "Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects". Braz J Med Biol Res 34 (2): 177–82. doi:10.1590/S0100-879X2001000200004. PMID 11175492. Free full text

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

English Journal

Biodegradation of clofibric acid and identification of its metabolites.

Salgado R1, Oehmen A, Carvalho G, Noronha JP, Reis MA.
Journal of hazardous materials.J Hazard Mater.2012 Nov 30;241-242:182-9. doi: 10.1016/j.jhazmat.2012.09.029. Epub 2012 Sep 24.
Clofibric acid (CLF) is the pharmaceutically active metabolite of lipid regulators clofibrate, etofibrate and etofyllinclofibrate, and it is considered both environmentally persistent and refractory. This work studied the biotransformation of CLF in aerobic sequencing batch reactors (SBRs) with mixe
PMID 23062606

Methods of chromatographic determination of medicines decreasing the level of cholesterol.

Kublin E1, Kaczmarska-Graczyk B, Malanowicz E, Mazurek AP.
Acta poloniae pharmaceutica.Acta Pol Pharm.2010 Sep-Oct;67(5):455-61.
With reference to common application of HPLC to routine analytical tests on medicinal products decreasing the level of cholesterol, including three compounds from this group--fenofibrate, bezafibrate and etofibrate, we developed a new method for determining two other compounds--ciprofibrate and gemf
PMID 20873411

[Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].

Emmerich KH1, Poritis N, Stelmane I, Klindzane M, Erbler H, Goldsteine J, Görtelmeyer R.
Klinische Monatsblätter für Augenheilkunde.Klin Monbl Augenheilkd.2009 Jul;226(7):561-7. doi: 10.1055/s-0028-1109516. Epub 2009 Jul 30.
INTRODUCTION: Diabetic retinopathy is the leading cause of vision loss or blindeness in working-age adults in the developed and developing countries. No curative treatments are available for diabetic retinopathy and the most common symptomatic treatment, laser photocoagulation, provides only partial
PMID 19644802

Japanese Journal

Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia

Exp Clin Endocrinol Diabetes 111, 322-324, 2003
NAID 30015584442

Related Pictures

★リンクテーブル★

リンク元	「エトフィブラート」「エトフィブレート」

「エトフィブラート」

Etofibrate
Systematic (IUPAC) name
	2-[(pyridin-3-yl)carbonyloxy]ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	?
Pharmacokinetic data
Metabolism	Hydrolyzed to clofibric acid and niacin
Identifiers
CAS number	31637-97-5
ATC code	C10AB09
PubChem	CID 65777
ChemSpider	59197
UNII	23TF67G79M
KEGG	D07187
ChEMBL	CHEMBL358150
Chemical data
Formula	C18H18ClNO5
Mol. mass	363.792 g/mol
	SMILES O=C(OCCOC(=O)C(Oc1ccc(Cl)cc1)(C)C)c2cccnc2;
	InChI InChI=1S/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3 ; Key:XXRVYAFBUDSLJX-UHFFFAOYSA-N ;
(what is this?) (verify);